TOP TEN perturbations for 38884_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38884_at
Selected probe(set): 210107_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38884_at (210107_at) across 6674 perturbations tested by GENEVESTIGATOR:

colorectal cancer study 1 / normal colon tissue

Relative Expression (log2-ratio):-8.667025
Number of Samples:6 / 6
Experimental colorectal cancer study 1
Laser microdissected human colorectal cancer sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)

Relative Expression (log2-ratio):7.527831
Number of Samples:4 / 2
Experimental rectal cancer study 2 (post; chemoradiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; no therapy)
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

rectal cancer study 2 (post; radiotherapy) / rectal cancer study 2 (post; chemoradiotherapy)

Relative Expression (log2-ratio):-6.6733227
Number of Samples:4 / 4
Experimental rectal cancer study 2 (post; radiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after treatment with short-course neoadjuvant radiotherapy (RT; 25Gy in 5 fractions). Samples were collected after 1 week of completing the therapy. Patients were selected for neoadjuvant RT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation, and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; chemoradiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):-6.400385
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

colorectal cancer study 33 (carcinoma; colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-5.8933964
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

rectal cancer study 2 (post; no therapy) / rectal cancer study 2 (pre; no therapy)

Relative Expression (log2-ratio):-5.8371325
Number of Samples:2 / 2
Experimental rectal cancer study 2 (post; no therapy)
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (pre; no therapy)
Tumor tissue samples obtained during a diagnostic biopsy from the rectum of patients with rectal adenocarcinoma. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

colorectal cancer study 9 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-5.0561333
Number of Samples:4 / 4
Experimental colorectal cancer study 9 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

colorectal cancer study 9 (metastatic progression) / adjacent colon tissue (metastatic progression)

Relative Expression (log2-ratio):-4.658477
Number of Samples:3 / 3
Experimental colorectal cancer study 9 (metastatic progression)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression.
Control adjacent colon tissue (metastatic progression)
Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM).

colorectal cancer study 25 / adjacent colon tissue

Relative Expression (log2-ratio):-4.6183376
Number of Samples:94 / 17
Experimental colorectal cancer study 25
Human primary colorectal carcinoma sample.
Control adjacent colon tissue
Normal colon tissue samples adjacent to tumor from patients with colorectal cancer.

colorectal cancer study 30 / normal colorectal tissue

Relative Expression (log2-ratio):-4.616001
Number of Samples:45 / 4
Experimental colorectal cancer study 30
Formalin-fixed-paraffin-embedded (FFPE) colorectal tissue samples from patients with colorectal cancer.
Control normal colorectal tissue
Healthy, non-tumor colorectal tissue.